Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Immix Biopharma, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
FAQ
- What is Immix Biopharma, Inc.'s EBIT?
- Immix Biopharma, Inc. (IMMX) reported EBIT of -$10.8M in Q1 2026.
- How has Immix Biopharma, Inc.'s EBIT changed year-over-year?
- Immix Biopharma, Inc.'s EBIT decreased by 130.7% year-over-year, from -$4.68M to -$10.8M.
- What is the long-term trend for Immix Biopharma, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s EBIT has grown at a 117.0% compound annual growth rate (CAGR), from -$1.35M to -$29.96M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Immix Biopharma, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude